tiprankstipranks
Trending News
More News >
Ashland (ASH)
NYSE:ASH
Advertisement

Ashland (ASH) AI Stock Analysis

Compare
287 Followers

Top Page

ASH

Ashland

(NYSE:ASH)

Select Model
Select Model
Select Model
Neutral 54 (OpenAI - 4o)
Rating:54Neutral
Price Target:
$51.00
▲(2.22% Upside)
Ashland's overall stock score reflects significant profitability challenges and mixed technical signals. The earnings call provided some positive outlooks, particularly in margin maintenance and future growth potential. However, valuation concerns and ongoing operational challenges weigh on the score.
Positive Factors
Margin Sustainability
The expansion of adjusted EBITDA margins indicates improved operational efficiency and cost management, which can enhance profitability over the long term.
Cash Generation Ability
Strong cash generation and liquidity position provide Ashland with the financial flexibility to invest in growth opportunities and weather economic downturns.
Manufacturing Optimization
The manufacturing optimization program is expected to yield significant cost savings, enhancing long-term profitability and competitive positioning.
Negative Factors
Profitability Challenges
Persistent profitability challenges and declining revenue growth highlight operational inefficiencies that could hinder long-term financial performance.
Intermediates Segment Challenges
Ongoing challenges in the Intermediates segment could continue to pressure overall revenue and margins, affecting Ashland's market position in this area.
Weaker Coatings Demand
Sustained weak demand for coatings in key markets could impact sales and profitability, limiting growth prospects in the Specialty Additives segment.

Ashland (ASH) vs. SPDR S&P 500 ETF (SPY)

Ashland Business Overview & Revenue Model

Company DescriptionAshland Global Holdings Inc. (ASH) is a global leader in specialty chemicals, focused on providing innovative solutions in various sectors including personal care, pharmaceuticals, food and beverage, and construction. The company offers a wide range of products such as adhesives, coatings, and specialty polymers that enhance performance and sustainability for its customers. With a commitment to sustainability and innovation, Ashland operates across multiple regions, serving diverse industries with a portfolio that emphasizes high-value applications and customer-centric solutions.
How the Company Makes MoneyAshland generates revenue primarily through the sale of specialty chemicals and materials across its diverse product portfolio. The company's revenue model is driven by several key streams, including the provision of various chemical formulations tailored for specific applications in industries such as personal care, pharmaceuticals, and food. Additionally, Ashland benefits from long-term contracts and partnerships with customers that provide stable revenue. The company also invests in research and development to innovate and improve existing products, which helps to create new revenue opportunities. Strategic collaborations and acquisitions further enhance Ashland's market position, contributing to its overall earnings.

Ashland Earnings Call Summary

Earnings Call Date:Nov 04, 2025
(Q4-2025)
|
% Change Since: |
Next Earnings Date:Feb 03, 2026
Earnings Call Sentiment Neutral
Ashland demonstrated resilience in maintaining margins and achieving expected EBITDA despite sales declines driven by portfolio optimization. Successes in Life Sciences and Personal Care were notable, but challenges remain in the Intermediates segment and demand for coatings. Cash generation and liquidity are strong, but higher tax rates and delayed optimization benefits pose challenges.
Q4-2025 Updates
Positive Updates
Resilient Performance Amid Macroeconomic Challenges
Ashland maintained strong margins and achieved revenue and EBITDA in line with expectations despite ongoing macroeconomic challenges. Adjusted EBITDA was $119 million, marking a 5% increase on a comparable basis.
Life Sciences and Personal Care Success
Life Sciences saw continued demand for high-value cellulosic excipients, tablet coatings, and injectables. Personal Care generated broad-based gains with strong volume growth, outperforming a muted market environment.
Manufacturing Optimization Initiative
The $60 million manufacturing optimization program is underway, with $5 million in savings this year and $18 million projected next year, aiding margin improvements.
Strong Adjusted EBITDA Margins
Adjusted EBITDA margin expanded to 24.9%, up 110 basis points from last year, marking the most profitable quarter of the year.
Steady Cash Generation and Improved Liquidity
Ongoing free cash flow totaled $52 million with total liquidity standing at just over $800 million. A $103 million tax refund improved net leverage to closer to mid-2s.
Negative Updates
Sales Decline Due to Portfolio Optimization
Q4 sales were $478 million, down 8% year-over-year, primarily due to portfolio optimization initiatives.
Intermediates Segment Challenges
Intermediates faced pricing and volume pressure, with sales down 8% year-over-year and adjusted EBITDA margins compressing due to lower pricing and production volumes.
Weaker Coatings Demand
Coatings demand remained weak, especially in China, India, and North America, negatively impacting the Specialty Additives segment.
Higher Effective Tax Rate Impacts Earnings
Adjusted earnings per share were down 14% from the prior year, disproportionately impacted by a higher effective tax rate.
Delayed Benefits from Manufacturing Optimization
The realization of benefits from the manufacturing optimization program is extending beyond initial expectations due to various operational challenges.
Company Guidance
During the fourth quarter of fiscal year 2025, Ashland reported sales of $478 million, an 8% decrease year-over-year, largely due to portfolio optimization initiatives. Adjusted EBITDA was $119 million, down 4% from the previous year, with margins expanding to approximately 25%. The company highlighted that excluding the impact of portfolio optimization, sales declined only 1%, and adjusted EBITDA actually increased by 5% on a comparable basis. Ashland's guidance for fiscal 2026 projects sales between $1.835 billion and $1.905 billion, reflecting organic growth of 1% to 5%, and an adjusted EBITDA range of $400 million to $430 million. The company anticipates a free cash flow conversion of 50% with capital expenditures near $100 million. Key factors influencing the guidance include approximately $30 million in savings from restructuring and network optimization, as well as a $20 million impact from resetting performance-based compensation and merit increases.

Ashland Financial Statement Overview

Summary
Ashland faces significant financial challenges with declining revenues, profitability issues, and reduced cash flow generation. The income statement shows a troubling trend with a significant decline in both revenue and profitability, including a net loss. The balance sheet indicates moderate stability but with declining equity. Cash flow has also decreased significantly, raising concerns about cash generation relative to earnings.
Income Statement
45
Neutral
The income statement reveals a troubling trend with a significant decline in both revenue and profitability. The TTM (Trailing-Twelve-Months) period shows a decrease in total revenue to $1.869 billion from $2.113 billion in the previous year, highlighting negative revenue growth. The gross profit margin decreased, and the net profit margin turned negative with a net loss of $873 million. Additionally, the EBIT and EBITDA margins are concerning as they are significantly negative, indicating operational challenges.
Balance Sheet
60
Neutral
The balance sheet indicates moderate stability with a debt-to-equity ratio of 0.79, which suggests a manageable level of leverage. However, the equity ratio has decreased over time, now at 40.9% in the TTM period. Stockholders' equity has also declined, pointing to reduced financial stability. The company needs to address its declining equity base to ensure sustained financial health.
Cash Flow
55
Neutral
The cash flow statement shows a decline in free cash flow from $325 million to $69 million over the TTM period, indicating a significant drop in free cash flow growth rate. Operating cash flow remains positive but has decreased compared to previous years. The free cash flow to net income ratio is negative due to net losses, which raises concerns about cash generation relative to earnings.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.82B2.11B2.19B2.39B2.11B2.02B
Gross Profit534.00M618.00M668.00M830.00M670.00M599.00M
EBITDA-528.00M303.00M457.00M509.00M448.00M-254.00M
Net Income-844.00M169.00M178.00M927.00M220.00M-508.00M
Balance Sheet
Total Assets4.62B5.64B5.94B6.21B6.61B6.88B
Cash, Cash Equivalents and Short-Term Investments207.00M300.00M417.00M646.00M210.00M454.00M
Total Debt1.49B1.47B1.46B1.38B2.10B1.99B
Total Liabilities2.73B2.78B2.84B2.99B3.86B3.84B
Stockholders Equity1.89B2.87B3.10B3.22B2.75B3.04B
Cash Flow
Free Cash Flow116.00M274.00M73.00M-326.00M455.00M70.00M
Operating Cash Flow200.00M411.00M243.00M-213.00M560.00M203.00M
Investing Cash Flow-63.00M-51.00M-109.00M1.56B-381.00M8.00M
Financing Cash Flow-231.00M-479.00M-371.00M-896.00M-426.00M9.00M

Ashland Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price49.89
Price Trends
50DMA
50.18
Negative
100DMA
51.22
Negative
200DMA
52.98
Negative
Market Momentum
MACD
-0.02
Negative
RSI
51.48
Neutral
STOCH
69.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASH, the sentiment is Neutral. The current price of 49.89 is above the 20-day moving average (MA) of 49.57, below the 50-day MA of 50.18, and below the 200-day MA of 52.98, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 51.48 is Neutral, neither overbought nor oversold. The STOCH value of 69.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ASH.

Ashland Risk Analysis

Ashland disclosed 18 risk factors in its most recent earnings report. Ashland reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Ashland Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
$2.67B29.5336.39%1.90%4.98%30.84%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
58
Neutral
$2.39B-0.64%1.42%0.08%-107.33%
54
Neutral
$2.29B-34.45%3.29%-13.67%
49
Neutral
$1.89B-0.09%2.13%-4.49%-100.80%
48
Neutral
$1.74B-38.91%-13.39%88.25%
46
Neutral
$1.88B-69.74%4.91%2.12%-579.74%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ASH
Ashland
49.89
-26.74
-34.89%
IOSP
Innospec
75.07
-47.32
-38.66%
KWR
Quaker Chemical
139.95
-30.36
-17.83%
WDFC
WD-40 Company
198.01
-82.95
-29.52%
CC
Chemours Company
12.75
-6.22
-32.79%
NGVT
Ingevity
49.86
2.36
4.97%

Ashland Corporate Events

Ashland Global Holdings Reports Q4 2025 Earnings and 2026 Outlook
Nov 6, 2025

Ashland Global Holdings, Inc. is a global additives and specialty ingredients company that operates in high-quality, consumer-focused markets such as pharmaceuticals, personal care, and architectural coatings. The company recently released its fourth-quarter fiscal 2025 earnings report, highlighting a disciplined approach to navigating challenging market conditions.

Ashland Global’s Resilient Earnings Amid Challenges
Nov 6, 2025

Ashland Global Holdings, Inc. recently held its earnings call, demonstrating a resilient performance amidst macroeconomic challenges. The company successfully maintained margins and achieved expected EBITDA, despite experiencing sales declines due to portfolio optimization. Notable successes were seen in the Life Sciences and Personal Care sectors, although challenges persist in the Intermediates segment and coatings demand. Strong cash generation and liquidity were highlighted, but higher tax rates and delayed optimization benefits pose ongoing challenges.

Business Operations and StrategyFinancial DisclosuresM&A Transactions
Ashland Reports Q4 2025 Results Amid Sales Decline
Neutral
Nov 4, 2025

Ashland Inc. reported its fourth-quarter fiscal 2025 results, showing a sales decline to $478 million, down eight percent from the previous year, primarily due to Portfolio Optimization initiatives. Despite challenging market conditions, Ashland maintained strong margins and delivered consistent revenue and EBITDA, with growth in Personal Care and Life Sciences segments. The company received a $103 million tax refund related to the Nutraceuticals divestiture, strengthening its financial position. Ashland’s strategic focus on cost management and portfolio alignment positions it for future profit growth.

The most recent analyst rating on (ASH) stock is a Hold with a $60.00 price target. To see the full list of analyst forecasts on Ashland stock, see the ASH Stock Forecast page.

Executive/Board Changes
Ashland Board Member Sergio Pedreiro Resigns
Neutral
Sep 18, 2025

On September 16, 2025, Sergio Pedreiro resigned from Ashland, Inc.’s Board of Directors, including his roles on the Compensation Committee and as Chair of the Audit Committee, effective September 30, 2025. His resignation led to a reduction in the Board’s size from nine to eight members, and it was clarified that his departure was not due to any disagreements with the company’s practices.

The most recent analyst rating on (ASH) stock is a Hold with a $52.00 price target. To see the full list of analyst forecasts on Ashland stock, see the ASH Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 08, 2025